K
KalVista Pharmaceuticals, Inc. (KALV)
NGM – Real Time Price. Currency in USD
26.73
+0.02 (0.07%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
26.73
+0.02 (0.07%)
At close: May 12, 2026, 4:00 PM EDT
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
| Name | Position |
|---|---|
| Dr. Christopher L. Hamblett Ph.D. | Senior Vice President of Corporate Development |
| Dr. Christopher M. Yea Ph.D. | Chief Development Officer |
| Dr. Paul K. Audhya M.B.A., M.D. | Chief Medical Officer |
| Mr. Benjamin L. Palleiko | CEO & Director |
| Mr. Bilal Arif | Chief Operating Officer |
| Mr. Brian Krex J.D. | General Counsel |
| Mr. Brian Piekos | Chief Financial Officer |
| Mr. Ryan Baker | Head of Investor Relations |
| Ms. Linea Aspesi | Chief People Officer |
| Ms. Rachel M. Morten | Senior Vice President of Regulatory Affairs & QA |
| Date | Type | Document |
|---|---|---|
| 2026-04-30 | 10-KT/A | d121999d10kta.htm |
| 2026-04-29 | SC14D9C | ef20071871_sc14d9c.htm |
| 2026-04-29 | 8-K | ef20071670_8k.htm |
| 2026-03-25 | 10-KT | kalv-20251231.htm |
| 2026-01-26 | S-8 | d63436ds8.htm |
| 2026-01-08 | 8-K | d11988d8k.htm |
| 2025-11-10 | 10-Q | kalv-20250930.htm |
| 2025-10-06 | 8-K | d42627d8k.htm |
| 2025-10-02 | 8-K | d945945d8k.htm |
| 2025-09-29 | 8-K | d83242d8k.htm |